Can the Previous Therapeutic Control of the Main Risk Factors of Cerebrovascular Disease Influence the Acetylsalicylic Acid-Nonresponsive Status in Acute Ischemic Stroke Patients? Results from a Portuguese Prospective Cohort Study

• Tipo: Artigo em Revista Científica Internacional
• Data: 2015

Autores

Freitas Silva, M (Autor) FMUP; Goncalves, L (Autor) Outra; Rui Medeiros (Autor) ICBAS; José Pedro Nunes (Autor) FMUP

Revista

Título: Journal of Stroke and Cerebrovascular Diseases

Vol. 24

Páginas: 1383-1389

ISSN: 1052-3057

Editora: Elsevier

Indexação

ISI Web of Knowledge - 3 Citações

Scopus - 3 Citações

Outras Informações

ID Authenticus: P-00G-63J

DOI: 10.1016/j.jstrokecerebrovasdis.2015.02.021

Abstract (EN): Background: Acute ischemic stroke (AIS) is a complex disease, and the therapeutic control of its risk factors may influence the efficacy of acetylsalicylic acid (ASA) and the occurrence of new vascular events. The aim of this study was to investigate the potential in vivo properties of a previous treatment controlling the main risk factors of cerebrovascular disease, in the ASA-nonresponsive status in a Portuguese population. Methods: We conducted a prospective cohort study with the recruitment of 90 patients diagnosed with AIS and a follow-up protocol was set up with recurrent stroke as the main clinical end point under evaluation. At admission, PFA-100 (platelet function analyzer) test was evaluated in blood samples from AIS patients treated with 100 mg/day of ASA and previously treated with antihypertensive, antidiabetic, or statin drugs. Results: We observed that 30% of patients were ASA nonresponders. Multivariate regression analysis indicated that the previous treatment with antihypertensive drugs emerged with a significant risk reduction of an ASA-nonresponsive status (odds ratio,.119; 95% confidence interval,.026-. 538; P = .006). Furthermore, our results indicated an influence of ASA-nonresponsive status in a decreased period to a new recurrent stroke event in the time frame of 24 months (P = .005, log-rank test). Conclusions: ASA is an important part of treatment of AIS, and its efficacy may be improved in previous high-risk cerebrovascular patients, particularly with antihypertensive therapeutic control.

Idioma: Inglês

Tipo (Avaliação Docente): Científica

Nº de páginas: 7